FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 804 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How Are Eligibility Criteria for Clinical Trials Changing to Help People... June 10, 2021 ESMO Open: First Official Impact Factor of 5.329 June 30, 2020 FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer February 15, 2023 Nurse Who Battled Cancer While In School Surprises Her Dad With... March 1, 2021 Load more HOT NEWS ¿Puede una biopsia hacer que mi cáncer se disemine? Why the voices of people affected by cancer are critical to... FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients Self Destruction
